PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Swiss strike deal for COVAX to get 1 mln Moderna doses more quickly

Wed, 24th Nov 2021 12:00

By Stephanie Nebehay

GENEVA, Nov 24 (Reuters) - Switzerland has become the first
country to swap places in the supply queue for COVID-19
vaccines, allowing 1 million doses of the Moderna shot
to go first to the COVAX dose-sharing programme, the GAVI
vaccine alliance said on Wednesday.

GAVI, which leads COVAX's procurement and delivery of
supplies to low and middle income countries, called for other
governments to "slot-swap" and work with manufacturers to ensure
COVAX purchase agreements can be fulfilled as a priority.

"Through this collaboration, 1 million doses of the Moderna
vaccine originally planned to be delivered to Switzerland will
instead be made available to COVAX in Q4 2021. Switzerland will
then take COVAX’s place in the queue, and receive these doses
later in 2022," the Geneva-based GAVI said in a statement.

Switzerland's voluntary vaccination campaign has stalled,
with just over 65% of the population fully vaccinated.

COVAX, which is also backed by the World Health Organization
(WHO), has delivered some 507 million doses to 144 countries
since February.

But its pipeline was stymied for much of the year after
India halted vaccine exports in mid-April due to its own severe
epidemic. The Serum Institute of India (SII), the world's
biggest vaccine maker which produces a licensed version of the
AstraZeneca shot known as Covishield, was COVAX's main
supplier.

The resumption of India supplying COVID-19 vaccines to the
COVAX platform after eight months was delayed on Monday when
Nepal requested a postponement, two sources told Reuters.

"Despite initial supply setbacks, deliveries continue to
accelerate steadily and will continue to do so through the end
of the year and into 2022," GAVI said, without giving details.
(Reporting by Stephanie Nebehay
Editing by Mark Potter)

Related Shares

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly ...

8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...

8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4% *

8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.